Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
Johnson and Johnson
Dow
AstraZeneca
Mallinckrodt

Last Updated: May 26, 2022

LYMPHOSEEK KIT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

When do Lymphoseek Kit patents expire, and when can generic versions of Lymphoseek Kit launch?

Lymphoseek Kit is a drug marketed by Cardinal Health 414 and is included in one NDA. There are two patents protecting this drug.

This drug has thirty patent family members in twelve countries.

The generic ingredient in LYMPHOSEEK KIT is technetium tc-99m tilmanocept. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the technetium tc-99m tilmanocept profile page.

DrugPatentWatch® Generic Entry Outlook for Lymphoseek Kit

Lymphoseek Kit was eligible for patent challenges on March 13, 2017.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 27, 2033. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign up for a Free Trial

Summary for LYMPHOSEEK KIT
International Patents:30
US Patents:2
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Clinical Trials: 24
DailyMed Link:LYMPHOSEEK KIT at DailyMed
Drug patent expirations by year for LYMPHOSEEK KIT
DrugPatentWatch® Estimated Generic Entry Opportunity Date for LYMPHOSEEK KIT
Generic Entry Date for LYMPHOSEEK KIT*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
INJECTABLE;INJECTION

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for LYMPHOSEEK KIT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
John O. PriorEarly Phase 1
Stanford UniversityPhase 2
Anna CrucetaPhase 4

See all LYMPHOSEEK KIT clinical trials

US Patents and Regulatory Information for LYMPHOSEEK KIT

LYMPHOSEEK KIT is protected by two US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of LYMPHOSEEK KIT is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting LYMPHOSEEK KIT

Macromolecular carrier for drug and diagnostic agent delivery
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Compositions for radiolabeling diethylenetriaminepentaacetic acid (DTPA)-dextran
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

FDA Regulatory Exclusivity protecting LYMPHOSEEK KIT

NEW PATIENT POPULATION
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cardinal Health 414 LYMPHOSEEK KIT technetium tc-99m tilmanocept INJECTABLE;INJECTION 202207-001 Mar 13, 2013 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Cardinal Health 414 LYMPHOSEEK KIT technetium tc-99m tilmanocept INJECTABLE;INJECTION 202207-001 Mar 13, 2013 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Cardinal Health 414 LYMPHOSEEK KIT technetium tc-99m tilmanocept INJECTABLE;INJECTION 202207-001 Mar 13, 2013 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for LYMPHOSEEK KIT

When does loss-of-exclusivity occur for LYMPHOSEEK KIT?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 10208624
Estimated Expiration: See Plans and Pricing

Brazil

Patent: 1007487
Estimated Expiration: See Plans and Pricing

Canada

Patent: 50230
Estimated Expiration: See Plans and Pricing

China

Patent: 2301429
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 92012
Estimated Expiration: See Plans and Pricing

Patent: 84965
Estimated Expiration: See Plans and Pricing

Japan

Patent: 43905
Estimated Expiration: See Plans and Pricing

Patent: 40276
Estimated Expiration: See Plans and Pricing

Patent: 09796
Estimated Expiration: See Plans and Pricing

Patent: 33892
Estimated Expiration: See Plans and Pricing

Patent: 12516328
Estimated Expiration: See Plans and Pricing

Patent: 15164933
Estimated Expiration: See Plans and Pricing

Patent: 17066148
Estimated Expiration: See Plans and Pricing

Patent: 19178133
Estimated Expiration: See Plans and Pricing

Patent: 21088566
Estimated Expiration: See Plans and Pricing

South Korea

Patent: 1713559
Estimated Expiration: See Plans and Pricing

Patent: 1765717
Estimated Expiration: See Plans and Pricing

Patent: 110115148
Estimated Expiration: See Plans and Pricing

Patent: 170027874
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering LYMPHOSEEK KIT around the world.

Country Patent Number Title Estimated Expiration
Japan 2017066148 ジエチレントリアミン五酢酸(DTPA)−デキストランを放射標識するための組成物 (COMPOSITION FOR RADIOLABELING DIETHYLENETRIAMINEPENTAACETIC ACID (DTPA)-DEXTRAN) See Plans and Pricing
Canada 2750230 COMPOSITIONS DE RADIOMARQUAGE D'ACIDE DIETHYLENETRIAMINEPENTAACETIQUE (DTPA)-DEXTRAN (COMPOSITIONS FOR RADIOLABELING DIETHYLENETRIAMINEPENTAACETIC ACID (DTPA)-DEXTRAN) See Plans and Pricing
Japan 2015164933 ジエチレントリアミン五酢酸(DTPA)−デキストランを放射標識するための組成物 (COMPOSITIONS FOR RADIOLABELING DIETHYLENETRIAMINEPENTAACETIC ACID (DTPA)-DEXTRAN) See Plans and Pricing
European Patent Office 2392012 COMPOSITIONS DE RADIOMARQUAGE D'ACIDE DIÉTHYLÈNETRIAMINEPENTAACÉTIQUE (DTPA)-DEXTRAN (COMPOSITIONS FOR RADIOLABELING DIETHYLENETRIAMINEPENTAACETIC ACID (DTPA)-DEXTRAN) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for LYMPHOSEEK KIT

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1178838 122015000033 Germany See Plans and Pricing PRODUCT NAME: TILMANOCEPT; REGISTRATION NO/DATE: C(2014) 8901 FINAL 20141119
1178838 1590025-1 Sweden See Plans and Pricing PRODUCT NAME: TILMANOCEPT; REG. NO/DATE: EU/1/14/955 20141120
1178838 300736 Netherlands See Plans and Pricing PRODUCT NAME: TILMANOCEPT, DESGEWENST GELABELD MET TECHNETIUM TC 99M; REGISTRATION NO/DATE: EU/1/14/955 20141119
1178838 15C0033 France See Plans and Pricing PRODUCT NAME: TILMANOCEPT; REGISTRATION NO/DATE: EU/1/14/955 20141121
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
Moodys
Dow
Baxter
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.